Clinical experience with the use of rhG-CSF in secondary autoimmune neutropenia.
This paper outlines the impact of granulocyte-colony stimulating factor (G-CSF) used as a single modality therapy in 17 patients with secondary autoimmune neutropenia (S-AIN) who had been treated a multiple number of times previously. Fifteen of these patients had demonstrable antineutrophil antibodies and two had cellular S-AIN with haemopoietic inhibitory T-cells present in the marrow. Prior to treatment, all had had problems with infection. All patients responded within 7 days of commencement of treatment. Provided G-CSF neutrophil counts were maintained above 1 x 109/l, no further infections occurred. This was achievable by using G-CSF administered as infrequently as once every 8 days. Eight of the 17 patients remained on G-CSF, although five switched to the glycosylated form because of side-effects. None have developed osteoporosis despite 47.29 patient years of total experience with G-CSF. In conclusion both glycosylated and nonglycosylated G-CSF can be used effectively in treating AIN on a long-term basis.
Smith
M A
MA
Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol, UK. ann3.smith@uwe.ac.uk
Smith
J G
JG
D000293:Adolescent; D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D001856:Bone Marrow Examination; D003114:Colony-Forming Units Assay; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D000069585:Filgrastim; D006031:Glycosylation; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D009504:Neutrophils / Q000276:immunology; D010024:Osteoporosis / Q000139:chemically induced; D011994:Recombinant Proteins; D012646:Self Administration; D013156:Splenectomy; D016176:T-Lymphocyte Subsets / Q000276:immunology; D016896:Treatment Outcome
D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim